Skip to main content
. 2024 Sep 30;15(9):704. doi: 10.1038/s41419-024-07082-x

Fig. 3. Gilteritinib induces cholesterol accumulation in lung cancer cells by accelerating its biosynthesis and inhibiting ABCA1-mediated cholesterol efflux.

Fig. 3

A After 48 h treatment with 100 nM gilteritinib, the expression of ABCA1 in A549 and H1650 cells was measured by qRT-PCR. B After treatment with 100 nM gilteritinib at the indicated time points, the expression of ABCA1 in A549 and H1650 cells was measured by western blot. C Efficiency of stable overexpression of ABCA1 in gilteritinib-treated A549 and H1650 cells was verified by western blot. D The effect of ABCA1 overexpression on free cholesterol in gilteritinib-treated A549 cells was detected by filipin staining. E qRT-PCR was used to test ABCG1 mRNA expression in A549 and H1650 cells treated with 100 nM gilteritinib. F The prognostic value of ABCG1 in lung cancer patients was assessed by the Kaplan–Meier plotter analysis. **P < 0.01, ***P < 0.001.